Breast cancer studies suggest that interleukin 6 (IL-6) acts as a regulator of estrogen synthesis and aromatase activity, mediates a growth response related to hormone receptor status, and contributes to pro-metastatic processes including epithelial-to-mesenchymal transition, cell invasion, cell migration, and mesenchymal stem cell recruitment [5–7]. The gene discussed is IL6; the disease is breast carcinoma.